Electronic Quality of Life Reporting for Post-Pediatric Liver Transplant (SPaRO Trial)

N/A

Waitlist Available

Led By Eyal Shemesh, MD

Research Sponsored by University of Pittsburgh

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be younger than 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 24 months

Awards & highlights

No Placebo-Only Group

Summary

This trial uses a smartphone application/web interface to collect reports of a pediatric liver transplant recipient's quality of life from the child and parent, in order to evaluate how well the application can help integrate these evaluations into care.

Who is the study for?

This trial is for pediatric liver transplant recipients aged over 8 and under 20 years, who had their transplant at least a year ago. They must speak English or Spanish well enough to understand the study and have internet access. It's not for those planning to change medical services within a year.

What is being tested?

The study tests how well a smartphone app/web interface can collect quality of life reports from kids with liver transplants and their parents. The goal is to see if these reports can help improve care by using the Pediatric Liver Transplant Quality of Life questionnaire.

What are the potential side effects?

Since this trial involves answering questionnaires through an app or web interface, there are no direct physical side effects like you'd expect with medication. However, participants may experience stress or discomfort while reflecting on their quality of life.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 24 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~24 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Secondary study objectives

Implementation metric

Medication level variability index (MLVI)

Patient baseline quality of life (child report on PeLTQL)

+3 more

Other study objectives

Rejection

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Pediatric liver transplant recipientsExperimental Treatment1 Intervention

As this is a single arm trial, all eligible liver transplant recipients and their caregivers will be enrolled in this arm. Eligible participants are children who received a liver transplant at least 1 year prior to enrollment at a participating SNEPT center and continue to receive their post-transplant care at that center.

Do I qualify?Apply below to find out